NextCure Stock Forecast, Price & News

NextCure's stock was trading at $38.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NXTC shares have decreased by 78.1% and is now trading at $8.38.
View which stocks have been most impacted by COVID-19.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for NextCure.

NextCure is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for NextCure.

NextCure Inc (NASDAQ:NXTC) issued its earnings results on Thursday, August, 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.03. NextCure had a negative return on equity of 8.43% and a negative net margin of 65.22%.
View NextCure's earnings history.

9 equities research analysts have issued 1-year target prices for NextCure's stock. Their forecasts range from $11.00 to $87.00. On average, they anticipate NextCure's stock price to reach $32.70 in the next year. This suggests a possible upside of 290.2% from the stock's current price.
View analysts' price targets for NextCure.

NextCure saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 1,970,000 shares, an increase of 8.8% from the August 15th total of 1,810,000 shares. Based on an average daily volume of 857,800 shares, the days-to-cover ratio is currently 2.3 days. Currently, 12.1% of the shares of the company are sold short.
View NextCure's Short Interest.

Some companies that are related to NextCure include Gossamer Bio (GOSS), Vectura Group (VEGPF), Enanta Pharmaceuticals (ENTA), Amphastar Pharmaceuticals (AMPH), Akouos (AKUS), Morphic (MORF), Passage Bio (KROS), Pliant Therapeutics (PLRX), Endo International (ENDP), Protagonist Therapeutics (PTGX), Phibro Animal Health (PAHC), VBI Vaccines (VBIV), RAPT Therapeutics (RAPT), Frequency Therapeutics (FREQ) and Provention Bio (PRVB).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include SCYNEXIS (SCYX), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), BioNano Genomics (BNGO), Kadmon (KDMN), Novan (NOVN), OrganiGram (OGI), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and DHT (DHT).

(NXTC) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO.

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

NextCure's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Great Point Partners LLC (3.63%), Cormorant Asset Management LP (2.52%), Hillhouse Capital Advisors LTD. (2.32%), Jennison Associates LLC (1.69%), Matthews International Capital Management LLC (0.92%) and Federated Hermes Inc. (0.41%). Company insiders that own NextCure stock include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan.
View institutional ownership trends for NextCure.

NXTC stock was sold by a variety of institutional investors in the last quarter, including Hillhouse Capital Advisors LTD., Great Point Partners LLC, Marshall Wace North America L.P., Bank of America Corp DE, Cormorant Asset Management LP, and Nuveen Asset Management LLC.
View insider buying and selling activity for NextCure.

NXTC stock was purchased by a variety of institutional investors in the last quarter, including Matthews International Capital Management LLC, Federated Hermes Inc., Point72 Asset Management L.P., Asymmetry Capital Management L.P., Two Sigma Advisers LP, SG Americas Securities LLC, Swiss National Bank, and Vident Investment Advisory LLC. Company insiders that have bought NextCure stock in the last two years include Sofinnova Venture Partners Ix,, Stella Xu, and X LP Canaan.
View insider buying and selling activity for NextCure.

Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NXTC stock can currently be purchased for approximately $8.38.

NextCure has a market capitalization of $230.59 million and generates $6.35 million in revenue each year. The company earns $-33,740,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis.

The official website for NextCure is www.nextcure.com.

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected]